Euglena Co., Ltd. (Headquarters: Minato-ku, Tokyo; President: Mitsuru Izumo; hereinafter 'Euglena') held a media briefing to introduce 'CONC LABO Hyalo-Cica Rich Shot,' a targeted beauty serum designed to provide both moisture and firmness for skin prone to dryness and instability, set to launch on March 16, 2026 (Monday). This is a report on the event. CONC Hyalo-Cica Rich Shot

Addressing concerns such as loss of firmness, elasticity, dryness, and skin instability that often arise with age, Takashi Ando, Senior Brand Manager at Euglena, introduced this product as a new skincare proposal—an 'injectable serum' that combines 'offensive' anti-aging care with 'defensive' skin protection, utilizing an approach featuring Hyaluronic Acid*3 and CICA extract*4 (Centella Asiatica extract).

Takashi Ando, Senior Brand Manager, Cosmetics Planning and Development Department, Euglena Co., Ltd. Joined Euglena Co., Ltd. in 2006, participating as a launch manager for the healthcare business. Following the company's listing on the TSE Mothers (now TSE Growth Market) in 2012, he was involved in launching the in-house cosmetics brand business. He became Brand Manager for the CONC brand in 2021 and has held his current position since 2023. He focuses on creating new beauty value through open-innovation development, leveraging the company's strengths as a biotechnology venture.

Excerpt from the presentation slides

From 'Applying' to 'Piercing': What is the new approach proposed by CONC? Ando: 'The CONC LABO series is a functional brand based on the concept of translating medical inspiration into daily skincare. As the demand for aesthetic medicine grows, we are providing a professional-grade experience...'

FACT BOX

  • Source: PR Times
  • Category: News